The Big Gut: Are Excess GH and Insulin to Blame?
Written by Dan Gwartney, M.D.
Sunday, 15 February 2009
A lot has already been said over the last two decades about the decline of symmetry and aesthetics in bodybuilding. Traditionally, elite level bodybuilders were graced with Olympian lines, similar to the figures Michelangelo and other classical artists and sculptors carved and drew in places of worship. These visages were gradually replaced in the late 1980ís with more exaggerated physiques, and in some cases big guts! The Foundation Principles
The big gut has not escaped the notice of the leadership of the IFBB who recently posted a mandate dictating a change in judging criteria.1 Recalling the founding principles on which the sport of bodybuilding was created, the IFBB is reaffirming the significance of balance, proportion and classic attributes such as the ďVĒ-taper and a flat, muscular abdomen. The mandate didnít state what pressures may have incited the de facto change in judging criteria, but noted that distended abdomens and distorted muscles negatively impact symmetry and natural aesthetics, detracting from the overall physique.
As the mandate clearly comments on the proliferation of distended abdomens and the distorted muscles that have become the hallmark of contemporary bodybuilders, itís important for competitive bodybuilders to understand the potential causes for this appearance. There have been numerous message board discussions debating the relative contribution of a number of factors, some with merit and others without. Muscle distortion likely refers to the unnatural lumps and bulges appearing in the muscle bellies from the use of inflammatory compounds such as nolotil and synthol.2,3 Injecting these compounds causes the muscle tissue to swell around the area of the injection depot. Done properly, this can lead to significantly enlarged muscle, but poor technique can lead to unsightly lumps, suggesting a golf ball-sized tumor is growing in the deltoid or biceps.
Abdominal distension is a completely separate issue. Younger followers of bodybuilding may not be aware of the classical appearance, which personified the golden era of the sport. Bodybuilders used to appear as heavily muscled athletes, gracefully portraying the images adorning Greek temples or the fantasy artwork of Boris Vallejo.4 During the later half of the 1980ís, changes began to appear in the professional bodybuildersí physique, culminating in the look now dominating the field of competitors.
Gone are the days when the waistline of a bodybuilder was waspishly tiny, replaced by abdominal girths equaling the titanic proportions of the chest and upper back. When the trophies are handed out and the champions receive back-slapping hugs from other competitors, it looks more like a tachi-ai charge in a sumo match. Yet, unlike their sumo counterparts, todayís bodybuilders are extremely lean, even more so than their more aesthetic forebears.
Despite the prodigious guts, which look capable of launching a reptilian creature, like a scene from the movie ďAlien,Ē the skin is so thin and subcutaneous fat so low that muscles, veins and tendons are readily apparent. Those in the know are aware of the direct causes of abdominal distension, while others guess. Itís important to dispel irrelevant factors, as they serve only to confuse the issue. The abdominal distension seen in todayís bodybuilders isnít due to intestinal gas, obesity due to overeating or use of powerlifting movements. Todayís bodybuilders are very sophisticated in regard to diet and itís extremely unlikely that any, let alone every pro would be downing grams of maltitol or fiber laxatives immediately before walking on stage. As was stated earlier, the bodybuilders of today have extremely low subcutaneous body fat. The guts arenít due to generalized obesity. In the off-season, many of these athletes relax their standards and tend to accumulate body fat, some to the point of obesity, but this isnít a factor on stage during competition. Causes for the Big Gut
While power movements are still part of the training regimen for many bodybuilders, such moves donít account for the gut. Powerlifters tend to have a more portly appearance, but this is due to higher body fat levels, low aerobic capacity and weakening and/or stretching of the abdominal wall from repeated high intra-abdominal pressure exercises. Powerlifters may also acquire hernias, which can deform the abdominal wall.5 The primary factors leading to the dramatic belly bulging are the abusive levels of GH and insulin use.
GH, human growth hormone, was originally provided in very limited supply to dwarf children as it was sourced from the brains of cadavers.6 During the 1970ís, advances in genetic engineering allowed for the relatively unlimited production growth hormone using recombinant technology.7 By the late 1980ís, GH was readily available and being used by athletes in many sports, including football, cycling and bodybuilding.8 GH was found to be effective in promoting connective tissue health, speeding recovery, reducing body fat and enhancing anabolic growth.9
As is the case with most drugs, bodybuilders applied trial and error to determine the optimal dosing schedule of GH for achieving maximum growth. During this time, endorsements and trophies were won by those who achieved the most exaggerated growth. This system of rewards promoted the use of excessively high doses of GH, upward to 36 International Units (IU) per day.
Despite the relative benefits of extreme muscular growth, bodybuilders began to develop adverse side effects. For those familiar with the field of endocrinology, the study of hormonesí effects on the body, these side effects were not unexpected. Strange, disfiguring growths of the ears, nose and jaw change facial shape, hands and feet enlarge and the abdomen protrudes being pushed outward by the growth of thoracic (chest) and abdominal (gut) organs.10,11
These features are identical to those experienced by people suffering from the disease acromegaly, which is caused by tumors producing high levels of GH in an unregulated fashion.12 Acromegaly is similar to gigantism, a disease state which begins in childhood, resulting in extreme height and features of acromegaly. The primary difference is the lack of effect of acromegaly on height, as the growth plates of adults are fused, preventing further height changes.
The question might be raised ďWhy use so much GH and could less be used?Ē Itís impossible to say who started using GH, but itís likely the first bodybuilders mimicked the doses used to treat dwarf children who are very short due to GH deficiency. These children are provided weekly with 0.3 milligrams per kilogram (2.2 pounds bodyweight); extrapolating those numbers to massive adult bodybuildersí size results in a daily dose of 15Ė25 IU per day.13
Obviously, some bodybuilders have exceeded even those numbers as the price of GH has dropped with the introduction of Asian imports. The high dose of GH is desirable, or was in the days of size for sizeís sake, because the anabolic effects of GH are dose dependent. The more GH used, the larger the muscles (head, organs, hands and feet) grew.14 However, as has been seen on stage and in the clinical realm, exceeding a reasonable dose of GH can lead to problems.
Studies have shown levels as low as six IU per day can lead to early signs of acromegaly, which include physiological changes (insulin resistance) as well as the disfiguring alterations in appearance.15,16 When GH is low in adults, clinical features are noted, including: central (waist) obesity, weak bones, unhealthy cholesterol and fat levels, reduced muscle, decreased exercise tolerance, depression and anxiety.17,18 These features are resolved with GH replacement therapy, which can be used safely for years if IGF-1 levels are measured to ensure excess hormone isnít being administered.18,19 IGF-1 is a protein growth factor, which is produced in response to GH and is responsible for many of its anabolic effects.
Ironically, though GH provides wonderful benefits up to a point, when itís provided beyond what the body can tolerate, it can induce the disfiguring changes of acromegaly and lead to the development of the metabolic syndrome. The metabolic syndrome is a collection of risk factors relating to poor health and early death. The Pathway to Ultimate Size
The central features of the metabolic syndrome are: obesity (especially intra-abdominal fat), dangerous cholesterol and fat levels in the blood, fatty buildup in the liver, insulin resistance, high blood pressure, type 2 diabetes and heart attacks.17 Inflammation has also been suggested to be part of the metabolic syndrome.20 The exceedingly high levels of GH used by some bodybuilders predispose them to symptoms of metabolic syndrome by interfering with the bodyís ability to respond to insulin.19,21 This leads to elevated levels of both insulin and sugar, causing fat cells to grow, making it difficult to break down stored fat and get sugar for energy into the muscle cell. The fat releasing (lipolytic) effect of GH appears to be strong enough to counteract the insulin resistance of fat cells in the subcutaneous layer, but another very important reservoir of fat, the visceral fat surrounding the abdominal organs, grows. As the visceral fat deposit enlarges, physiologic changes occur in the body which make the metabolic syndrome more pronounced, worsen Heart Health and promote cardiovascular disease.22,23
These effects compound the heart-altering effect of anabolic steroids and GH, placing many of these bodybuilders at great risk for a heart attack.24,25
Beyond the gut-bulging effect of GH (acting by increasing heart, liver, spleen and intestine size as well as increasing the visceral fat), thereís also the effect of insulin. Not only do these bodybuilders already have high natural insulin levels due to the GH-induced insulin resistance, but they also administer insulin for its potent anabolic effect.26 Insulin is the primary anabolic hormone of the body, funneling sugar and other nutrients into active tissue and maintaining fat stores for periods of starvation. Though itís less popular now than it was five to 10 years ago, bodybuilders felt taking insulin before meals, along with daily GH injections, was the pathway to ultimate size. In a way, they were right, in that the amount of size put on by these athletes was tremendous. Unfortunately, insulin can lead to a severe hypoglycemic reaction, a potentially fatal drop in blood sugar, which hospitalizes many diabetics every year.27 The use of insulin to induce a fatal hypoglycemic event was implicated in the attempted murder case of tycoon Claus von Bulow, whose wife remains in a coma after 20 years.28 Many others have used insulin as a murder weapon, including serial killer William Archerd of California.29
The size insulin puts on a bodybuilder is not quality size. Muscle growth does occur, especially in the presence of insulin resistance, but fat content is also higher, as is water retention. All fat cells will grow in the presence of insulin, including visceral fat content.30 Bodybuilders can control subcutaneous fat with lipolytic drugs (GH, clenbuterol, etc.) and water retention with diuretics, but visceral fat is very difficult to combat in the setting of insulin resistance. Given the lack of significant additional muscular growth, potential risks and need for additional drugs to counteract the negative effects of insulin, itís falling out of favor.
A big bellyó it has a place in the last trimester of a pregnancy, but not on stage in bodybuilding. The introduction of recombinant human growth hormone and a relative abundance of supply make this the drug of choice to support the anabolic effects of steroids and drop body fat to previously unattainable levels. Unfortunately, the more is better mentality, fueled by the dose-response relationship between GH, IGF-1 and anabolic effects, has lead to an epidemic of as many as three unwanted and dangerous side effects. Chronic overdosing of GH may lead to: 1) growth of the organs of the chest and abdomen causing the ďGH gutĒ look and risking heart failure, 2) facial disfigurement and abnormal growth of the hands, and 3) feet and symptoms of the metabolic syndrome (vascular disease, diabetes and high blood pressure). Adding insulin to the chemical arsenal increases many of these risks, promotes the growth of the visceral (intra-abdominal) fat, increases water retention and exposes bodybuilders to potentially fatal hypoglycemic events.
There really is no place for insulin in a healthy pursuit of bodybuilding. Itís a potent anabolic hormone, but its benefits donít outweigh the risks and the side effect of fat storage and water retention also need to be addressed. GH is being used with great benefit in a broad range of people, including athletes. Many of its benefits can be experienced using much more moderate doses of one to five IU per day, six days per week.9,18,31-33 Itís important to monitor IGF-1 levels to ensure the body isnít being overexposed to GH as each personís need are individualized and may vary over time.32 The benefits of connective tissue healing, fat mobilization and augmenting the anabolic effect of exercise and steroids can be experienced with these lower and more rational doses.9 References:
1. Manion J. IFBB Symmetry Aesthetics Mandate, 2005 April 13.
2. Llewellyn W. Nolotil (metamizol). Anabolics, 2005 Body of Science Publishing, Jupiter, FL;2005:323.
3. Llewelln W. Synthol. Anabolics, 2005, Body of Science Publishing, Jupiter, FL;2005:324.
4. Vallejo B. Dreams: The art of Boris Vallejo. Thunderís Mouth Press, ISBN 1560252804;1999.
5. Dickerman RD, Smith A, et al. Umbilical and bilateral inguinal hernias in a veteran powerlifter: is it a pressure-overload syndrome? Clin J Sport Med, 2004 Mar;14(2):95-6.
6. Preece MA. Diagnosis and treatment of children with growth hormone deficiency. Clin Endocrinol Metab, 1982 Mar;11(1):1-24.
7. Jenkins D, Stewart PM. Advances in medical therapy for pituitary disease: treating patients with growth hormone excess and deficiency. J Clin Pharm Ther, 1993 Jun;18(3):155-63.
8. Bidlingmaier M, Wu Z, et al. Doping with growth hormone. J Pediatr Endocrinol Metab, 2001 Sep-Oct;14(
9. Doessing S, Kjaer M. Growth hormone and connective tissue in exercise. Scand J Med Sci Sports, 2005 Aug;15(4):202-10.
10. Ezzat S. Hepatobiliary and gastrointestinal manifestations of acromegaly. Dig Dis, 1992;10(3):173-80.
11. Colao A, Marzullo P, et al. Prostatic hyperplasia: an unknown feature of acromegaly. J Clin Endocrinol Metab, 1998 Mar;83(3):775-9.
12. Ezzat S, Forster MJ, et al. Acromegaly. Clinical and biochemical features in 500 patients. Medicine, 1994 Sep;73(5):233-40.
13. Mauras N, Attie KM, et al. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. J Clin Endocrinol Metab, 2000 Oct;85(10):3653-60.
14. Burgess E, Wanke C. Use of recombinant human growth hormone in HIV-associated lipodystrophy. Curr Opin Infect Dis, 2005 Feb;18(1):17-24.
15. Sas T, Mulder P, et al. Carbohydrate metabolism during long-term growth hormone treatment in children with short stature born small for gestational age. Clin Endocrinol, 2001 Feb;54(2):243-51.
16. Jeffcoate W. Growth hormone therapy and its relationship to insulin resistance, glucose intolerance and diabetes mellitus: a review of recent evidence. Drug Saf, 2002;25(3):199-212.
17. Johannsson G, Bengtsson BA. Growth hormone and the metabolic syndrome. J Endocrinol Invest, 1999;22(5 Suppl):41-6.
18. Cerro AL. Long-term challenges in growth hormone treatment. Horm Res, 2004;62(suppl 4):23-30.
19. Monson JP. Monitoring of insulin-like growth factors during growth hormone treatment: adulthood growth hormone deficiency. Endocr Dev, 2005;9:89-99.
20. Esposito K, Giugliano D. The metabolic syndrome and inflammation: association or causation? Nutr Metab Cardiovasc Dis, 2004 Oct;14(5):228-32.
21. Takano A, Haruta T, et al. Growth hormone induces cellular insulin resistance by uncoupling phosphatidylinositol 3-kinase and its downstream signals in 3T3-L1 adipocytes. Diabetes, 2001 Aug;50(
22. Kobayashi H, Nakamura T, et al. Visceral fat accumulation contributes to insulin resistance, small-sized low-density lipoprotein and progression of coronary artery disease in middle-aged non-obese Japanese men. Jpn Circ, 2001 Mar;65(3):193-9.
23. Bonora E. Relationship between regional fat distribution and insulin resistance. Int J Obes Relat Metab Disord, 2000 Jun;24 Suppl 2:S32-5.
24. Twickler TB, Cramer MJ, et al. Acromegaly and heart failure: revisions of the growth hormone/insulin-like growth factor axis and its relation to the cardiovascular system. Semin Vasc, Med 2004 May;4(2):115-20.
25. Urhausen A, Albers T, et al. Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Heart, 2004 May;90(5):496-501.
26. Llewelln W. Insulin. Anabolics, 2005 Body of Science Publishing, Jupiter, FL;2005:301-3.
27. McCrimmon RJ, Frier BM. Hypoglycemia, the most feared complication of insulin therapy. Diabete Metab, 1994 Nov-Dec;20(6):503-12.
28. Dershowitz A. Reversal of fortune: inside the van Bulow case, Random House, New York, ISBN 0394539036;1986.
29. McComb J. California Supreme Court. People v. Archerd, (1970) 3 C3d 615. [Crim. 13053, Cal Sup Ct, Dec 10, 1970].
30. Saiki A, Miyashita Y, et al. Reduction of visceral adiposity after operation in a subject with insulinoma. J Atheroscler Thromb, 2004;11(4):209-14.
31. de Boer H, Blok GJ, et al. Changes in subcutaneous and visceral fat mass during growth hormone replacement therapy in adult men. Int J Obes Relat Metab Disord, 1996 Jun;20(6):580-7.
32. Lustig RH. Optimizing growth hormone efficacy: an evidence-based analysis. Horm Res, 2004;62 Suppl 3:93-7.
33. Vigano A, Mora S, et al. Effects of recombinant growth hormone on visceral fat accumulation: pilot study in human immunodeficiency virus-infected adolescents. J Clin Endocrinol Metab, 2005;90(7):4075-80.